Patents by Inventor Percy Knolle

Percy Knolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigen-loaded chitosan nanoparticles for immunotherapy
    Patent number: 10369217
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 6, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
  • Vaccination strategy
    Patent number: 10195267
    Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: February 5, 2019
    Assignees: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN, TECH UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
    Inventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer
  • VACCINATION STRATEGY
    Publication number: 20160008460
    Abstract: In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 14, 2016
    Applicants: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN, TECHNISCHE UNIVERSITÄT MÜNCHEN, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GM
    Inventors: Percy Knolle, Li-Rung Huang, Mathias Heikenwälder, Ulrike Protzer